Roche's CT-388 weight loss drug shows promising trial results
CNBC — May 16, 2024, 03:00 PM UTC
Summary: Roche's weight loss drug CT-388 showed promising results in a phase one trial, with patients losing up to 18.8% of their weight. The market for obesity drugs is projected to reach $100 billion by the end of the decade. CT-388 mimics gut hormones to suppress appetite and normalize blood sugar levels. Roche aims to compete with Novo Nordisk and Eli Lilly in the weight loss treatment market.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.